Chen et al. 2024

Quick Summary

This paper studied whether changes in the IRF2BPL gene might explain dystonia in people whose condition did not yet have a molecular diagnosis. Dystonia is a movement disorder in which muscles contract when they should not, causing twisting, abnormal postures, or repeated movements. Some people have dystonia as their main symptom, while others have dystonia together with seizures, developmental delay, ataxia, parkinsonism, or other neurological features.

The researchers studied 300 unrelated people in Taiwan with isolated or combined dystonia. They found one person with a disease-causing IRF2BPL variant. This person was an 18-year-old female with generalized dystonia, developmental regression, epilepsy, ataxic gait, speech delay, and cognitive difficulties. Her IRF2BPL variant was new in her, meaning it was not found in either parent.

The paper also compared this new patient with 60 previously published people with IRF2BPL-related disease. This comparison suggested that IRF2BPL variants in different parts of the protein may be linked with somewhat different symptom patterns. Variants in the polyglutamine, or poly Q, region were more often associated with epilepsy, while variants located before the first PEST region were more often associated with later onset, dystonia, ataxia, and motor regression.

Why This Paper Matters

Earlier IRF2BPL papers showed that this gene can cause a rare neurodevelopmental disorder with regression, seizures, speech problems, ataxia, dystonia, and other movement symptoms. However, most earlier reports began with people who already had neurodevelopmental symptoms, epilepsy, or broad neurological disease. This paper asked a more specific question: how often does IRF2BPL explain dystonia in a large group of people whose dystonia had not yet been genetically solved?

The answer was that IRF2BPL was rare in this setting. Among 300 unrelated patients with dystonia, only one had a disease-causing IRF2BPL variant. None of the 297 people with dystonia without epilepsy were found to have a pathogenic IRF2BPL variant. This helps families and clinicians understand that IRF2BPL can be part of the dystonia story, especially when dystonia occurs together with regression, seizures, or other neurological features, but it is not a common explanation for dystonia overall.

The paper also matters because it tried to connect a person's symptoms with the location of their IRF2BPL variant. The researchers did not just group variants by whether they were nonsense, frameshift, or missense changes. They also looked at where the variant sits in the IRF2BPL protein. This supported the idea that variants near the beginning of the protein, including the poly Q domain and the region before the first PEST sequence, may lead to a somewhat different clinical pattern than variants farther along the protein.

What The Researchers Studied

The main study was a genetic cohort study of 300 unrelated people with dystonia in Taiwan. All participants were enrolled from movement disorder clinics at National Taiwan University Hospital and Kaohsiung Chang Gung Memorial Hospital between January 2015 and July 2023. Their dystonia had not been explained by previous molecular testing.

Most of the cohort had isolated dystonia, meaning dystonia was the only major motor feature. This group included 256 of the 300 participants. The remaining 44 had combined dystonia, meaning dystonia occurred together with another neurological or movement feature. In the combined group, some had myoclonus, parkinsonism, ataxia, epilepsy, developmental delay, or more than one additional feature. In the combined dystonia group, dystonia was usually generalized rather than limited to one body area.

The researchers excluded people whose dystonia was likely due to a secondary cause, such as neuroleptic medication, cerebral palsy, traumatic injury, or certain structural brain lesions. They also excluded people who already had pathogenic variants in known dystonia or parkinsonism genes based on earlier testing and their current exome data.

All 300 participants had whole exome sequencing. This is a genetic test that reads the protein-coding parts of the genome, where many disease-causing variants are found. The researchers filtered out common variants and focused on rare changes that could affect protein function. Candidate variants were evaluated with prediction tools and variant-classification guidelines. The IRF2BPL variant found in the index patient was confirmed with Sanger sequencing, and parental testing showed that it was not present in either parent.

The paper also included a systematic review of previously published IRF2BPL cases. The researchers searched PubMed for published reports using IRF2BPL and the older gene name C14orf4. They combined their new patient with 60 previously reported patients and compared symptoms according to where each person's variant was located in the IRF2BPL protein.

What Was Learned About Symptoms

In the primary Taiwanese dystonia cohort, one 18-year-old female was found to have a de novo IRF2BPL variant. "De novo" means the genetic change was new in her and was not detected in either parent. She was the only child of healthy, unrelated parents and had no known family history of neurological disease.

Her early development was mixed. The paper reports that she reached motor milestones at first, but she had speech delay. At age 4, she gradually developed strabismus, which means the eyes are not aligned, and she began to lose motor skills. At age 13, she developed an ataxic gait, generalized dystonia, and generalized tonic-clonic seizures. An ataxic gait means walking is unsteady or poorly coordinated. Generalized dystonia means dystonia affects multiple body regions rather than staying in one area.

By age 18, her neurological exam showed reduced cognitive function, left eye esotropia, generalized dystonia, and myoclonus in both lower limbs, worse on the right side. Myoclonus means sudden, brief jerking movements. Her walking pattern was described as mixed dystonic and ataxic, meaning both abnormal muscle posturing and poor coordination contributed to how she walked.

Her brain MRI showed thinning of the corpus callosum. The corpus callosum is the structure that connects the two sides of the brain. The MRI did not show signal changes or structural lesions in the basal ganglia, a brain region often discussed in movement disorders. Her awake EEG showed generalized epileptic discharges mixed with focal epileptic activity. A dopamine transporter imaging study did not show reduced uptake in the basal ganglia.

The researchers also reported that several laboratory tests were unremarkable, including blood count, liver and kidney function tests, ceruloplasmin, autoimmune profiles, urine organic acids, and plasma tandem mass metabolite analysis. In plain language, those tests did not identify another clear cause for her symptoms.

When the researchers compared all 61 known IRF2BPL patients, including the new patient and 60 from the literature, they found that symptoms varied. Across the larger literature-combined group, some people had developmental delay from early life, some had regression after a period of development, and some had movement symptoms such as dystonia or ataxia. Epilepsy was common in some genetic subgroups but not universal across all groups.

The poly Q domain group included 29 people. Among people in this group with available data, epilepsy was reported in 13 of 14, or about 93%. Dystonia was reported in 11 of 28, or about 39%. Ataxia was reported in 25 of 29, or about 86%. Initial global developmental delay was reported in 6 of 22, while motor regression was reported in 5 of 22 and language regression in 2 of 20. MRI findings varied: among those with available MRI data, some had normal imaging, some had cerebral, cerebellar, or brainstem atrophy, and some had corpus callosum atrophy.

The variable region group included 28 people. In this group, dystonia was reported in 8 of 23, ataxia in 14 of 24, epilepsy in 12 of 25, motor regression in 10 of 26, and language regression in 7 of 26. The researchers then split the variable region into variants before and after the first PEST region. This comparison suggested an important pattern: people with variants before the first PEST region had later average onset, more motor regression, more dystonia, and more ataxia than people whose variants were after the first PEST region. People with variants after the first PEST region had more early global developmental delay in this comparison.

The paper does not say that every person with an IRF2BPL variant will follow one exact course. Instead, it supports a broad pattern: IRF2BPL-related disease can include developmental differences, regression, epilepsy, dystonia, ataxia, speech or language problems, cognitive changes, and variable MRI findings. Which symptoms are most prominent may depend partly on where the variant is located, but the numbers are still small.

What Was Learned About Genetics

The Taiwanese index patient had the IRF2BPL variant c.379C>T, also written at the protein level as p.Gln127Ter. This is a nonsense variant. In plain language, a nonsense variant changes one DNA letter in a way that creates an early stop signal. Instead of making the full IRF2BPL protein, the cell is predicted to stop building it much too soon.

The normal IRF2BPL protein has 796 amino acids. The p.Gln127Ter variant is predicted to stop the protein at amino acid 127. This would remove much of the protein, including regions thought to be important for where the protein goes inside the cell and how it functions. The paper specifically notes predicted loss of the nuclear localization sequence and the C-terminal C3HC4-type RING finger domain. The C-terminal RING finger domain is important because IRF2BPL has been linked to protein regulation through the ubiquitin-proteasome system, a cellular system that helps tag and remove proteins.

The variant was not found in the gnomAD population database and was classified as pathogenic under ACMG guidelines. Sanger sequencing confirmed the variant in the patient and showed that it was absent from both parents. This supported the conclusion that it was a de novo disease-causing variant.

The p.Gln127Ter variant sits in the N-terminal poly Q domain of IRF2BPL. "Poly Q" refers to a stretch of glutamine amino acids in the protein. The authors explain that this part of IRF2BPL is within a region related to the protein's coiled-coil structure. Their computational modeling predicted that the p.Gln127Ter variant would markedly truncate the protein.

When the researchers looked across the literature-combined group, they divided variants into four protein-location groups: the N-terminal poly Q domain, the poly A domain, the variable region, and the C-terminal C3HC4-type RING finger domain. They found that all variants in the poly Q domain were nonsense variants. In contrast, the small number of variants in the poly A and C3HC4 groups were frameshift variants. The variable region included nonsense, frameshift, and a small number of missense variants.

This location-based analysis was one of the main contributions of the paper. The authors found that poly Q domain variants had a higher reported rate of epilepsy than variants in other regions. They also found that variants before the first PEST sequence block were associated with later onset and more frequent dystonia and ataxia than variants after the first PEST sequence block. These findings suggest that the position of an IRF2BPL variant may matter, not only the general type of variant.

Patient And Cohort Details

The primary cohort included 300 unrelated people with dystonia. Their average age at symptom onset was about 43 years, and about 40% were male. Thirty-seven had symptom onset before age 20. Sixty-one had a family history of dystonia, but none came from a known consanguineous family.

Most participants, 256 of 300, had isolated dystonia. The remaining 44 had combined dystonia. Within the combined group, the additional features included myoclonus, parkinsonism, ataxia, epilepsy, and developmental delay. Three people had both epilepsy and developmental delay in addition to dystonia.

Only one person in the entire cohort had a pathogenic IRF2BPL variant. This means IRF2BPL explained 0.33% of the full dystonia cohort. The variant was found in a patient with generalized dystonia together with epilepsy and neurodevelopmental regression. The researchers did not find pathogenic IRF2BPL variants in the 297 people who had dystonia without epilepsy.

The index patient had several features that fit the broader IRF2BPL-related disorder pattern: speech delay, motor regression, seizures, dystonia, ataxia, cognitive changes, and abnormal EEG. Her MRI finding of corpus callosum thinning also fit with the article's broader discussion that MRI can be abnormal in some people with IRF2BPL-related disease, although normal MRIs also occur.

The literature-combined analysis included 61 total patients: 60 previously reported patients plus the new patient from this study. The largest location groups were the poly Q domain group with 29 people and the variable region group with 28 people. The poly A domain and C3HC4-type RING finger domain groups each had only 2 people, so findings from those two groups are especially limited.

Across the literature-combined group, most reported variants were truncating variants, meaning they were nonsense or frameshift changes predicted to shorten or disrupt the protein. Only two patients in the combined review had missense pathogenic variants, where one amino acid is changed to another rather than creating an early stop or frameshift.

The authors also noted that only four individuals in the literature-combined group were documented to have an affected parent with a heterozygous variant consistent with autosomal dominant inheritance. This means many reported cases appear to be de novo. For families, that is an important observation: a child or adult can have an IRF2BPL-related condition even when there is no known family history.

What Families Can Take Away

This paper supports IRF2BPL as one possible genetic cause of dystonia when dystonia occurs together with other neurological features such as developmental regression, epilepsy, ataxia, speech delay, or cognitive changes. It also shows that IRF2BPL is not a common cause of dystonia overall, at least in this Taiwanese cohort.

The study may be especially relevant for families whose child had some early development followed by loss of skills, new movement problems, and seizures. The index patient in this paper first had speech delay, then motor regression, then later ataxia, generalized dystonia, and seizures. Another previously reported person with the same p.Gln127Ter variant was described by the authors as having a similar pattern, with ataxia or dystonia appearing before epilepsy.

The paper also suggests that the exact location of an IRF2BPL variant may help researchers and clinicians understand possible symptom patterns. A variant in the poly Q domain or before the first PEST region may not mean the same clinical course for every person, but these locations may be worth noting when families review genetic results with their care team.

For families, the practical message is careful but hopeful in the information sense: genetic testing can sometimes give a name to a complex neurological condition, even when there is no family history. A diagnosis can help families connect with the right specialists, understand what has been reported in similar cases, and avoid a long search for other explanations. However, this paper does not provide a treatment plan, and it does not show that any specific therapy works for IRF2BPL-related dystonia or epilepsy.

Every person with an IRF2BPL variant is different. Decisions about seizure treatment, movement disorder care, therapy supports, feeding or swallowing evaluation, school planning, mobility equipment, and surveillance should be made with the person's own medical team.

Limits Of The Paper

The main dystonia cohort was large for a rare-disease genetic study, but only one person in that cohort had an IRF2BPL variant. That means the paper is helpful for showing that IRF2BPL is rare in this setting, but the primary cohort alone cannot define the full range of IRF2BPL-related dystonia.

Much of the genotype-phenotype analysis depended on previously published cases. Those earlier reports were collected from the medical literature, and not every paper reported every symptom in the same way. For example, some percentages in Tables 1 and 2 use smaller denominators because data were missing for some features. This makes the patterns useful but not final.

The poly A and C3HC4-type RING finger domain groups were very small, with only two people each. Comparisons involving those groups should be interpreted cautiously. A difference that appears large may change as more people are reported.

The paper used computational protein modeling to predict how the p.Gln127Ter variant could affect IRF2BPL protein structure and function. This supports the likely harmful effect of the variant, but modeling is not the same as a direct laboratory experiment in patient neurons.

The study also does not prove that variant location alone determines symptoms. Other factors may matter, including genetic background, medical history, age, variant mechanism, and differences in how symptoms were recognized and reported. The paper supports genotype-phenotype correlations, but more cases and functional studies are needed.

Finally, the study does not provide evidence for specific treatments. It describes symptoms, genetic findings, imaging, EEG, and possible mechanisms, but it does not test a therapy for IRF2BPL-related disease.

Source Notes

* Uploaded PDF: full article text, tables, and figures. * Main text: Abstract, Introduction, Methods, Results, Discussion. * Methods: Participants, whole exome sequencing, variant analysis, Sanger sequencing, systematic review of previous IRF2BPL reports, statistical analysis, in silico modeling. * Results: Taiwanese dystonia cohort description; index patient clinical description; IRF2BPL c.379C>T (p.Gln127Ter) variant interpretation; literature-combined genotype-phenotype analysis. * Figure 1: Brain MRI, EEG, and dopamine transporter imaging for the index patient. * Figure 2: Family pedigree, Sanger sequencing confirmation, and IRF2BPL protein-domain map showing reported variants. * Figure 3: In silico protein structures of wild-type and p.Gln127Ter mutant IRF2BPL. * Table 1: Clinical and genetic features of patients with IRF2BPL variants grouped by protein domain. * Table 2: Clinical and genetic comparison of variable-region variants before and after the first PEST region.

Quick Summary

This 2024 paper asked whether changes in the *IRF2BPL* gene might explain some cases of dystonia in Taiwan. Dystonia is a movement disorder where muscles contract in ways that can cause twisting, abnormal postures, or repetitive movements. The researchers studied 300 unrelated people whose dystonia did not yet have a molecular diagnosis.

The study found one person with a disease-causing *IRF2BPL* variant. She was an 18-year-old female with a de novo stop variant, `c.379C>T (p.Gln127Ter)`. "De novo" means the variant was new in her and was not inherited from either parent.

The article also compared this patient with 60 people from earlier *IRF2BPL* publications. Those comparison rows are useful for understanding patterns, but they are not new primary patients from this paper.

Why This Paper Matters

This paper matters because it connects *IRF2BPL* to the movement-disorder clinic setting. Earlier reports had already shown that *IRF2BPL* can cause developmental delay or regression, seizures, ataxia, and abnormal movements. Chen et al. looked from the other direction: among people already being evaluated for dystonia, how often is *IRF2BPL* the explanation?

The answer in this cohort was rare but real. One person out of 300 carried a pathogenic *IRF2BPL* variant. That does not make *IRF2BPL* a common cause of dystonia, but it supports including the gene when dystonia appears together with epilepsy, developmental regression, ataxia, or other neurological features.

The paper also adds genotype-phenotype context. The authors compared variants in different parts of the IRF2BPL protein and suggested that variants in different domains may have different clinical patterns.

What The Researchers Studied

The researchers enrolled 300 unrelated Taiwanese patients with molecularly unassigned dystonia. Most had isolated dystonia, while a smaller group had combined dystonia with other neurological findings such as myoclonus, parkinsonism, ataxia, epilepsy, or developmental delay.

All enrolled participants had whole exome sequencing. The authors filtered the sequencing results for rare coding variants and reviewed candidate variants using prediction tools, population databases, ACMG-style interpretation, and Sanger sequencing confirmation.

For *IRF2BPL*, they found one pathogenic variant in the cohort. The article then compared this patient with previously published *IRF2BPL* cases to look for relationships between variant location and symptoms.

What Was Learned About Symptoms

The index patient had early speech delay, while early motor milestones were described as achieved. At about 4 years of age, she developed strabismus and began losing motor skills.

At 13 years, she developed ataxic gait, generalized dystonia, and generalized tonic-clonic seizures. By age 18, the neurological exam described reduced cognitive function, left eye esotropia, generalized dystonia, lower-limb myoclonus, and a mixed dystonic and ataxic gait.

Her EEG was abnormal, with generalized epileptic discharges mixed with focal epileptic activity. Brain MRI showed thinning of the corpus callosum, without reported signal changes or structural lesions in the basal ganglia.

For families, the most practical symptom message is that *IRF2BPL* may be relevant when dystonia is not isolated, especially when it appears with seizures, regression, coordination problems, eye movement or alignment findings, and cognitive changes.

What Was Learned About Genetics

The reported variant was `c.379C>T (p.Gln127Ter)`. This is a nonsense, or stop, variant. In plain language, it places an early stop signal in the gene's instructions and is expected to shorten the protein.

The variant was de novo in the affected person. That strengthens the evidence that it was related to her neurological condition.

The authors located this change in the polyglutamine-rich N-terminal region of the IRF2BPL protein, before the first PEST sequence block. Their broader comparison suggested that people with variants in this region may have a recognizable mix of epilepsy, dystonia, ataxia, and later symptom onset compared with some other reported groups.

Patient And Cohort Details

For the verified cohort rebuild, this article contributes one primary patient row. That row represents the Taiwanese index patient directly reported by Chen et al. 2024.

The paper also discusses 60 previously published *IRF2BPL* patients. Those cases help the authors compare clinical patterns across the literature, but they are not counted as new primary observations for this website's verified cohort. Counting them as primary rows would double-count people already reported in earlier articles.

The cohort-screening result is also important: among 300 unrelated dystonia patients, only one had a pathogenic *IRF2BPL* variant. Among patients with non-epileptic dystonia, the authors did not find a pathogenic *IRF2BPL* variant.

What Families Can Take Away

1. *IRF2BPL* can be part of a dystonia workup when dystonia appears with epilepsy, developmental regression, ataxia, or cognitive changes. 2. A negative finding in most of this cohort means *IRF2BPL* is probably a rare explanation for dystonia, not a common one. 3. The exact variant and clinical context matter. This patient's stop variant is not the same as every other *IRF2BPL* change. 4. Literature-review tables are useful for comparison, but they should not be read as newly reported patients from this paper.

Limits Of The Paper

The primary *IRF2BPL* contribution is a single patient, so the article cannot predict the full range of outcomes for everyone with a similar variant.

The paper was built from a dystonia cohort, which means it may emphasize movement-disorder presentations more than epilepsy-first or developmental-clinic presentations.

The article provides a detailed narrative for the index patient, but it does not provide a separate patient-level table with every clinical field used in this website's cohort explorer.

The genotype-phenotype comparisons depend partly on previously published cases. Those comparisons can be helpful, but they are limited by small numbers and by differences in how earlier articles reported symptoms.

Source Notes

This summary is based on the public PMC full text and PubMed metadata for "Genetic analysis of IRF2BPL in a Taiwanese dystonia cohort: The genotype and phenotype correlation."

The verified cohort row uses the Results text and Figure 1 context for the index patient. The 60 previously published cases discussed by the article are treated as secondary review data and excluded from primary cohort counts.